Nektar Therapeutics (NKTR) Q2 2026 Earnings Call: REZPEG Phase III Advances
Source Tradingkey
Key Takeaways
- Nektar Therapeutics ended Q2 2026 with $1.02 billion in cash and investments and no debt. Management said the cash runway extends into Q3 2028, beyond the initial Phase III atopic dermatitis readouts expected in mid-2028.
- Q2 noncash royalty revenue was $10.1 million. Net loss totaled $40.6 million, or $1.23 per basic and diluted share.
- The global ZENITH-AD Phase III program for rezpegaldesleukin, or REZPEG, began randomizing patients in July. The first two studies target biologic- and JAK inhibitor-naive patients, while a treatment-experienced study is scheduled to begin by the end of September 2026.
- Following discussions with the FDA, Nektar finalized a single 850-patient registrational Phase III study for REZPEG in alopecia areata. The company plans to start ZENITH-AA in early 2027 and expects data in the second half of 2029.
- Nektar raised its year-end 2026 cash and investments guidance to $815 million-$840 million. Full-year revenue guidance remains $40 million-$45 million.
- Upcoming clinical catalysts include REZOLVE-AA off-treatment data in Q4 2026, atopic dermatitis off-treatment data in Q1 2027 and initial data from the TrialNet-sponsored type 1 diabetes study in 2027.
Core Financial Data
| Metric | Q2 2026 / Period End | Guidance or Context |
|---|---|---|
| Cash and investments | $1.02 billion | No debt; expected runway into Q3 2028 |
| Public offering proceeds | Approximately $350 million | Net proceeds from April 2026 offering |
| Noncash royalty revenue | $10.1 million | 2026 revenue guidance remains $40 million-$45 million |
| R&D expense | $39.1 million | 2026 guidance of $210 million-$230 million |
| G&A expense | $12.8 million | 2026 guidance of $60 million-$65 million |
| Noncash interest expense | $7.2 million | 2026 guidance of approximately $30 million-$35 million |
| Net loss | $40.6 million | $1.23 per basic and diluted share |
| Year-end cash and investments | — | Raised to $815 million-$840 million |
Business and Operating Performance
REZPEG Phase III program in atopic dermatitis
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
As of the European session on August 14, international spot copper prices (COPPER) continued to fluctuate near historical highs, trading around $14,070, down slightly by 0.3% intraday. De
WTI remains below $80.50 as traders monitor diplomatic efforts to reopen HormuzWest Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
West Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
Here is what you need to know on Thursday, August 13:
WTI declines below $82.50 as oil inventories rise far more than expectedWest Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
West Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
During Wednesday's Asian trading session, spot gold (XAUUSD) extended its rebound, reclaiming $4,400/oz. As of 11:08 Beijing time on August 12, spot gold was trading at $4,414.705/oz, up
